Publicaciones en colaboración con investigadores/as de Institute Catalá Oncología (15)

2020

  1. Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors

    Annals of Oncology, Vol. 31, Núm. 2, pp. 274-282

2017

  1. PheoSeq: A Targeted Next-Generation Sequencing Assay for Pheochromocytoma and Paraganglioma Diagnostics

    Journal of Molecular Diagnostics, Vol. 19, Núm. 4, pp. 575-588

  2. Strategies to design clinical studies to identify predictive biomarkers in cancer research

    Cancer Treatment Reviews, Vol. 53, pp. 79-97

2016

  1. Conditionally Replicative Adenoviruses-Clinical Trials

    Adenoviral Vectors for Gene Therapy: Second Edition (Elsevier Inc.), pp. 335-348

2015

  1. Analysis of heritability and shared heritability based on genome-wide association studies for thirteen cancer types

    Journal of the National Cancer Institute, Vol. 107, Núm. 12

  2. Characterization of large structural genetic mosaicism in human autosomes

    American Journal of Human Genetics, Vol. 96, Núm. 3, pp. 487-497

2014

  1. Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33

    Human Molecular Genetics, Vol. 23, Núm. 24, pp. 6616-6633

2009

  1. Oncolytic adenovirus retargeted to Delta-EGFR induces selective antiglioma activity

    Cancer Gene Therapy, Vol. 16, Núm. 3, pp. 256-265

2008

  1. E2F1 in gliomas: A paradigm of oncogene addiction

    Cancer Letters, Vol. 263, Núm. 2, pp. 157-163

2007

  1. Combination of the oncolytic adenovirus ICOVIR-5 with chemotherapy provides enhanced anti-glioma effect in vivo

    Cancer Gene Therapy, Vol. 14, Núm. 8, pp. 756-761

  2. ICOVIR-5 shows E2F1 addiction and potent antiglioma effect in vivo

    Cancer Research, Vol. 67, Núm. 17, pp. 8255-8263

2006

  1. Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan

    Clinical Cancer Research, Vol. 12, Núm. 2, pp. 556-562

2005

  1. Comparative effect of oncolytic adenoviruses with E1A or E1B-55 kDa deletions in malignant gliomas

    Neoplasia, Vol. 7, Núm. 1, pp. 48-56

  2. Downmodulation of E1A protein expression as a novel strategy to design cancer-selective adenoviruses

    Neoplasia, Vol. 7, Núm. 8, pp. 723-729

2004

  1. A novel E1A-E1B mutant adenovirus induces glioma regression in vivo

    Oncogene, Vol. 23, Núm. 10, pp. 1821-1828